Bioequivalence Requirements in the European Union: Critical Discussion
- 24 July 2012
- journal article
- review article
- Published by Springer Nature in The AAPS Journal
- Vol. 14 (4) , 738-748
Abstract
The aim of the present paper is to summarize the revised European Union (EU) Guideline on the Investigation of Bioequivalence and to discuss critically with respect to previous European requirements and present US Food and Drug Administration guidelines its more relevant novelties such as the following: in order to facilitate the development of generic medicinal products, the EU guideline includes the eligibility for Biopharmaceutics Classification System (BCS)-based biowaivers not only for BCS class I drugs but also for class III drugs with tighter requirements for dissolution and excipient composition. The permeability criterion of BCS classification has been substituted with human absorbability, as per the Biopharmaceutical Drug Disposition Classification System. The widening of the acceptance range for C max is possible only for highly variable reference products with an additional clinical justification. This scaled widening is carried out with a proportionality constant of 0.760 which is more conservative than the FDA approach and maintains the consumer risk at a 5% level when the intra-subject CV is close to 30%, due to the smooth transition between the scaled and the constant criteria. The guideline allows for the possibility of two-stage designs to obtain the necessary information on formulation differences and variability from interim analyses as a part of the pivotal bioequivalence study, instead of undertaking pilot studies. The guideline also specifies that the statistical analyses should be performed considering all factors as fixed, which has implications in the case of replicate designs.Keywords
This publication has 16 references indexed in Scilit:
- Computer simulations for bioequivalence trials: Selection of analyte in BCS drugs with first-pass metabolism and two metabolic pathwaysEuropean Journal of Pharmaceutical Sciences, 2010
- Computer simulations of bioequivalence trials: Selection of design and analyte in BCS drugs with first-pass hepatic metabolism: Part II. Non-linear kineticsEuropean Journal of Pharmaceutical Sciences, 2009
- Computer simulations of bioequivalence trials: Selection of design and analyte in BCS drugs with first-pass hepatic metabolism: Linear kinetics (I)European Journal of Pharmaceutical Sciences, 2009
- The Use of BDDCS in Classifying the Permeability of Marketed DrugsPharmaceutical Research, 2008
- Lack of bioequivalence between generic risperidone oral solution and originator risperidone tabletsInt. Journal of Clinical Pharmacology and Therapeutics, 2007
- Predicting Drug Disposition via Application of BCS: Transport/Absorption/ Elimination Interplay and Development of a Biopharmaceutics Drug Disposition Classification SystemPharmaceutical Research, 2005
- An eutomer/distomer ratio near unity does not justify non‐enantiospecific assay methods in bioequivalence studiesChirality, 2005
- Chiral BioequivalenceClinical Pharmacokinetics, 2000
- Truncated AUC evaluates effectively the bioequivalence of drugs with long half-lives.1997
- Comparison of Single and Multiple Dose Pharmacokinetics Using Clinical Bioequivalence Data and Monte Carlo SimulationsPharmaceutical Research, 1994